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To compare the risk of borderline ovarian tumors in women having in vitro fertilization (IVF) with 57 
women diagnosed with infertility but not having IVF. 58 
Methods 59 
This was a whole-population cohort study of women aged 20-44 years seeking hospital infertility 60 
treatment or investigation in Western Australia in 1982-2002.  Using Cox regression, we examined 61 
the effects of IVF treatment and potential confounders on the rate of borderline ovarian tumors.  62 
Potential confounders included parity, age, calendar year, socio-economic status, infertility 63 
diagnoses including pelvic inflammatory disorders and endometriosis and surgical procedures 64 
including hysterectomy and tubal ligation. 65 
Results 66 
Women undergoing IVF had an increased rate of borderline ovarian tumors with a hazard ratio (HR) 67 
of 2.46 (95% confidence interval [CI] 1.20–5.04).  Unlike invasive epithelial ovarian cancer, neither 68 
birth (HR 0.89; 95% CI 0.43–1.88) nor hysterectomy (1.02; 0.24–4.37) nor sterilization (1.48; 0.63–69 
3.48) appeared protective and the rate was not increased in women with a diagnosis of 70 
endometriosis (HR 0.31; 95% CI 0.04–2.29). 71 
Conclusions 72 
Women undergoing IVF treatment are at increased risk of being diagnosed with borderline ovarian 73 
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Borderline epithelial ovarian tumors are a heterogeneous group of neoplasms, first described in 81 
1929 [1].  For some time they were believed to be precursors of invasive epithelial ovarian cancer, 82 
but they have been gradually recognised as a separate entity and were classified as such by the 83 
International Federation of Gynecology and Obstetrics (FIGO) in 1970 [2].  Unlike invasive epithelial 84 
ovarian cancer, borderline epithelial ovarian tumors, also known as tumors of low malignant 85 
potential, have an indolent disposition, do not destructively invade the underlying ovarian stroma 86 
[3], are more likely to be diagnosed in women of reproductive age [4], and have a favourable 87 
prognosis, with more than 95% of women surviving five years beyond diagnosis [5].  They represent 88 
around 15% of all ovarian neoplasms [6].  89 
Some authors maintain that risk factors for borderline ovarian tumors are the same as those for 90 
invasive epithelial ovarian cancer, but the evidence is scant and contradictory.  For example, giving 91 
birth has been found to be protective in some studies [7, 8], possibly protective in another [9] and 92 
not protective in others [10-12].  Oral contraceptive use appears in some studies [9, 12] to confer 93 
protection, but not in others [7, 11].  Harris et al [8] found a protective effect of sterilization; 94 
Mosgaard et al [10] found no effect.  95 
With regard to treatment with fertility drugs, most studies have found an increased risk of 96 
borderline ovarian tumors after fertility drug treatment [8, 12-15], although some have not [10, 11].  97 
The only study that focussed specifically on in vitro fertilization (IVF) found that IVF treatment was 98 
associated with a four-fold increase in the risk of borderline ovarian tumors [16].  99 
Given the important role that IVF plays in the current management of infertility, we believe the 100 
relationship between IVF and borderline ovarian tumors deserves further investigation.  The aim of 101 
the present study was to examine the association between IVF treatment and risk of borderline 102 
ovarian tumors in a cohort of women seeking treatment for infertility, considering also the 103 
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confounding effects of known or potential ovarian cancer risk factors including parity, infertility 104 
diagnosis, sterilization, hysterectomy and socio-economic status.  105 
 106 
Methods 107 
The study cohort 108 
This was a population-based cohort study using routinely collected linked administrative data from 109 
an entire Australian State.  Methods for identifying the study cohort have been described in previous 110 
reports of breast [17] and ovarian cancer [18].  To recapitulate, we identified a cohort of women 111 
seeking hospital investigation and treatment for infertility at all hospitals in Western Australia (WA).  112 
The cohort was restricted to women who were known to be resident in WA according to the address 113 
attached to their hospital records, and who did not move out of the State according to the WA 114 
Electoral Roll, which had data available to us from 1988 onward.  115 
Women were included in the cohort if their hospital records contained a diagnosis of infertility or 116 
procreative management (ICD-9 628.0 - 628.9; ICD-10 N97.0 - N97.9 or ICD-9 V26.1 - V26.9; ICD-10 117 
Z31.1 - Z31.9), with their first such diagnosis occurring when they were aged between 20 and 44 118 
years.  The recruitment period for this study ranged from 1982 to 2002.  Data on exposures and 119 
outcomes (listed below) were collected in de-identified form from 1980 to 2010 using the resources 120 
of the WA Data Linkage System [19] which connects administrative datasets covering the whole 121 
population of WA.  The required information was obtained by accessing and combining de-identified 122 
data from six separate data collections: the Hospital Morbidity Data System, the WA Cancer Registry, 123 
the Midwives Notification System, the WA Deaths Register, the Reproductive Technology Register 124 
and the WA Electoral Roll.  These are statutory based data collections ensuring routine and complete 125 




Exposure variables 128 
The main exposure was IVF treatment.  Women undergoing IVF were identified from either the 129 
diagnostic and procedure codes contained in their hospital records, or by linkage to the 130 
Reproductive Technology Register.  Since 1993, all clinics in WA have been required by law to report 131 
all IVF cycles to this register. 132 
We also considered a number of potential confounders: those believed to influence the risk of 133 
invasive epithelial ovarian cancer, which may also impact on the risk of borderline ovarian tumors.  134 
These included diagnoses of endometriosis and pelvic inflammatory disorders (PID – ICD-9 614.0 - 135 
614.9; ICD-10 N70.1, N70.9, N73.0 - N73.9: predominantly 614.6 and N73.6 [pelvic peritoneal 136 
adhesions]), and procedures including tubal ligation, hysterectomy, unilateral oophorectomy or 137 
salpingo-oophorectomy (USO); parity (we compared parous women with nulliparous women), age at 138 
first birth, socio-economic status using the Index of Education and Occupation [20], and age and 139 
calendar year at the start of follow-up.  140 
We captured all births in WA during 1980 to 2010 and correctly recorded prior births in women who 141 
gave birth within the State during this time period.  However, some women may have delivered 142 
outside WA or prior to 1980 and not subsequently given birth in WA – this small proportion of 143 
women would have been incorrectly classified as nulliparous.  Similarly, all women who had a tubal 144 
ligation in WA between 1980 and 2010 were correctly classified, as were women who had a reversal 145 
with no mention of a prior sterilization.  However, there would remain a small proportion that had a 146 
tubal ligation outside the State or prior to 1980 without having a subsequent reversal, presumably 147 
going straight to IVF: sterilization status in this small proportion of women would have been 148 
incorrect.  We categorised women as having a diagnosis of endometriosis or PID if either of these 149 
was recorded at or on any record prior to the first infertility admission.  It is possible that some 150 
women would have been diagnosed later during follow-up or remained undiagnosed: these would 151 
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have been classified as not having endometriosis or PID, when in fact they did suffer from these 152 
conditions.  153 
 154 
 155 
Outcome variable 156 
The outcome was an incident diagnosis of borderline ovarian tumor, identified from data collected 157 
by the WA Cancer Registry.   158 
Data analysis 159 
Data were analysed using Cox regression analysis.  Women were followed from their first hospital 160 
infertility admission to the date of diagnosis of borderline ovarian tumor, date of bilateral 161 
oophorectomy/salpingo-oophorectomy, date of death or the censor date (15 August 2010), 162 
whichever came first.  Hazard ratios (HRs) were estimated in univariate and multivariate adjusted 163 
analysis for each of the exposure variables.  Covariates were entered into the model as either fixed 164 
or time dependent variables, depending on when they occurred or were measured.  Socio-economic 165 
status, age and calendar year were measured at baseline; endometriosis and pelvic inflammatory 166 
disorders were diagnosed at baseline.  These were entered into the regression model as fixed 167 
categorical variables.  Women gave birth either before or after the start of follow-up.  Birth (parous 168 
vs. nulliparous) and age group at first birth (less than 30 years and 30 years or older) were entered 169 
into separate models as categorical time dependent variables.  Tubal ligation could occur either 170 
before or after the start of follow-up; IVF could occur at the start of follow-up or sometime later; 171 
hysterectomy occurred after the start of follow-up.  These were all entered into Cox regression 172 
models as categorical time dependent variables to allow for the correct allocation of follow-up time 173 
into time before and time after exposure.  174 
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Characteristics of the study participants 181 
The eligible population included 22,045 women.  We excluded women who were not resident of WA 182 
or who were known to have moved out of WA (n=379) as well as women who were deemed to be no 183 
longer at risk of a borderline ovarian tumor diagnosis.  These included women who had a bilateral 184 
oophorectomy/salpingo-oophorectomy before their first infertility admission (n=13), women who 185 
had a diagnosis of invasive ovarian cancer either before or within six months of their first infertility 186 
admission (n=7) and women who were diagnosed with a borderline ovarian tumor before their first 187 
infertility admission (n=7).  None of the women in the cohort were diagnosed with borderline 188 
ovarian tumors within six months of their first infertility admission. The final cohort comprised a 189 
total of 21,639 women.   190 
Women were, on average, 31.2 years of age at their first infertility admission and were followed for 191 
a mean of 16.9 years.  Total observation of the cohort amounted to 365,775 woman-years.  Out of a 192 
total of 21,639 women, 31 were diagnosed with borderline ovarian tumors, including 17 women 193 
who had IVF and 14 women who did not.  The average age at diagnosis was 43.2 years (Table 1).  194 
Women having IVF were older at the birth of their first child and more likely to be in the upper 195 
quartile of the Index of Education and Occupation (Table 1).  196 
Borderline ovarian tumor risk factors 197 
We examined the association between IVF and potential confounding factors in univariate and then 198 
multivariate adjusted analyses (Table 2).  199 
IVF treatment was associated with an increased rate of borderline ovarian tumors in univariate and 200 
adjusted analysis.  The HR was 2.48 (95% confidence interval [CI] 1.22 – 5.04) in unadjusted analysis, 201 
and changed only slightly after adjustment for confounding by age, calendar year and socio-202 
economic status to 2.46 (95% CI 1.20 – 5.04) (Table 2).  203 
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In unadjusted analysis, there appeared to be a slight protective effect of giving birth, in particular 204 
giving birth at a young age, however, most of this apparent protection disappeared after adjustment 205 
for IVF, socio-economic status, age and calendar year (Table 2).  A part of this effect was due to 206 
confounding by IVF: women who gave birth, and women who gave birth at a young age were less 207 
likely to have had IVF (Table 1) and consequently appeared to have a reduced rate of borderline 208 
ovarian tumor diagnosis in the analysis that did not adjust for IVF.    209 
We also examined the effect of IVF in parous and nulliparous women separately.  In parous women 210 
the adjusted HR ratio associated with IVF treatment was 2.96 (95% CI 1.15 – 7.61); in nulliparous 211 
women it was 1.88 (95% CI 0.63 – 5.63).  212 
Women in the highest quartile of socio-economic status, as measured by the Index of Education and 213 
Occupation, had a reduced rate of borderline ovarian tumors.  This was particularly apparent in the 214 
adjusted analysis where the HR was 0.36 (95% CI 0.12 – 1.03) (Table 2).  Women undergoing IVF 215 
were more likely to be in the upper quartile of socio-economic status (Table 1) and adjusting for IVF 216 
allowed for a more accurate estimate of the effect of socio-economic status.  217 
We observed no association between a diagnosis of PID and the rate of borderline ovarian tumors, 218 
with an adjusted HR of 0.96 (95% CI 0.37 – 2.51) (Table 2).  We did not observe an increased rate 219 
with a diagnosis of endometriosis (adjusted HR 0.31, 95% CI 0.04 – 2.29) (Table 2).  We found no 220 
evidence for a protective effect of either sterilization or hysterectomy with HRs of 1.48 and 1.02 221 






The results of this study support the proposition that women undergoing IVF treatment are at 226 
increased risk of borderline ovarian tumors.  Within our cohort, the rate of diagnosis of borderline 227 
ovarian tumors was 2.5 times greater in women who sought infertility treatment and had IVF than in 228 
women who had infertility treatment but not IVF.   These findings are consistent with the only other 229 
study of IVF and borderline ovarian tumors [16], and also consistent with most studies of fertility 230 
drug treatment and borderline ovarian tumors [8, 12-15].   231 
A number of authors [14, 21-23] have suggested that this apparent increase in risk may not be 232 
causal, but rather due to surveillance bias.  Surveillance bias is a case of “the more you look, the 233 
more you find”; the premise being that women who have IVF will be examined more often than 234 
women who do not, providing more opportunities for detection.  Women undergoing IVF may be 235 
exposed to more routine examinations; or, because they are concerned about their IVF exposure, 236 
they may be more aware of symptoms of disease and be more pro-active in seeking diagnosis and 237 
treatment; alternatively they may be more health conscious and therefore actively seek screening.  238 
Any of these could lead to earlier detection and an apparent (though false) increase in risk of 239 
disease.   240 
This is a logical explanation, but is it true?  In order to answer this question, we considered the 241 
following: time from last infertility admission to diagnosis of borderline ovarian tumors, age at 242 
diagnosis, and risk of borderline tumors in women of high socio-economic status.  Women were 243 
diagnosed with borderline ovarian tumors, on average 8.6 years after their last hospital infertility 244 
admission.  Although there was some variability in the time to diagnosis, this considerable lapse of 245 
time suggests that borderline tumors were generally not being detected during routine infertility 246 
investigation.  This counters the first concern.   Secondly, if IVF women were more pro-active in 247 
seeking diagnosis and treatment, we would expect them to be diagnosed sooner, and at a younger 248 
age.  This was not the case.  The average time from last infertility admission to diagnosis in IVF 249 
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women was 9.4 years, and in women not undergoing IVF it was 7.3 years.  Furthermore, IVF women 250 
were diagnosed with borderline tumors at a mean age of 44.7 years, compared with 41.1 years in 251 
non-IVF women.  IVF women were not diagnosed sooner, or at a younger age.  Our third point is that 252 
if detection bias was the main reason for the apparent increase in risk of borderline tumors, we 253 
would expect women of higher socio-economic status to be more likely to be diagnosed, as they are 254 
generally found to be more active in seeking health screening [24].  This was also not the case.  We 255 
found that women of high socio-economic status had only one third the risk of borderline tumors 256 
compared with women of lower socio-economic status.   257 
We conclude, therefore, that the results of this study, although not offering definitive evidence in 258 
favour of a causal relationship, do not support the hypothesis that the observed increase in risk of 259 
borderline tumors after IVF treatment is due to detection bias.  260 
We considered a number of known ovarian cancer risk factors [25, 26], to determine whether they 261 
were also associated with the development of borderline ovarian tumors.  In contrast to previous 262 
studies of invasive epithelial ovarian cancer (for example, [18, 27]), we found no evidence for a 263 
protective effect of parity.  Neither sterilization nor hysterectomy appeared to confer any 264 
protection.   These observations support the proposition that borderline ovarian tumors are a 265 
separate entity with a different (and perhaps heteregenous) etiology.  Unfortunately, we had no 266 
information about other potential risk factors, including use of oral contraceptives and hormone 267 
replacement therapy.  268 
Like Pearce et al [28], we found no evidence for an increased risk of borderline tumors in women 269 
diagnosed with endometriosis, with an adjusted HR of 0.31 (95% CI 0.04 – 2.29).  This is in direct 270 
contrast to most research, including our own [18], on invasive epithelial ovarian cancer.  The reason 271 
for this could be because borderline tumors are generally found to be of serous and mucinous sub-272 
types [3] while endometriosis is more commonly associated with clear cell and endometrioid 273 
invasive ovarian cancer [28].  274 
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In summary, this study shows an increased rate of borderline ovarian tumors in women who 275 
undergo IVF treatment.  These are uncommon neoplasms, but with more and more couples relying 276 
on IVF to conceive, they may increase in number.  Continued data monitoring is warranted.  277 
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Table 1. Characteristics of the study cohort 1   368 
 369 
Characteristic All women in the 
cohort 
Women not 
undergoing IVF  
 
Women 
undergoing IVF  
Number of women 21,639 14,095 7,544 
Number of women who gave birth (%) 14,902 10,029 (71.1%) 4,873 (64.6%) 
Mean2 duration of follow-up (years)  16.9 ± 5.9 17.0 ± 5.9 16.7 ± 5.9 
Median duration of follow-up (years) 16.5  16.7 16.1  
Total duration of follow-up  
(person-years) 
365,775 240,069 125,706 
Mean age at first infertility admission 
(years) 
31.2 ± 5.2 30.8 ± 5.3 32.1 ± 4.8 
Mean age at first birth (years) 29.6 ± 6.0 28.4 ± 5.8 32.2 ± 5.4 
Number of women with a diagnosis of 
borderline ovarian tumor 
31 14 17 
Mean age at borderline ovarian tumor 
diagnosis (years) 
43.2 ± 7.5 41.1 ± 8.1 44.7 ± 6.9 
Median age at borderline ovarian 
tumor diagnosis (years) 
43.0 40.5 43.5 
Mean time from last infertility 
admission to borderline ovarian tumor 
diagnosis (years) 
8.6 ± 6.4 7.3 ± 5.6 9.4 ± 7.0 
20 
 
Median time from last infertility 
admission to borderline tumor 
diagnosis (years) 
8.2 7.5 10.8 
% of women in the upper quartile of 
the Index of Education and Occupation 
24 21 31 
 370 
1 The study cohort included all women in Western Australia seeking hospital investigation and 371 
treatment for infertility in the period 1982-2002 when they were aged between 20 and 44. 372 
2 All means are reported  + SD  373 
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Table 2. Potential borderline ovarian tumor risk and protective factors  374 
 375 
Exposure Number in 
exposed group 
Crude (unadjusted) HR 
(95% CI) 1 
Adjusted HR  
(95% CI) 2 
IVF 7,544 2.48 (1.22 – 5.04) 2.46 (1.20 – 5.04) 
Birth 3 14,902 0.70 (0.34 – 1.43) 0.89 (0.43 – 1.88) 
Age at first birth    
     No birth recorded  6,737 1.00 1.00 
     Age < 30 at first birth 7,047 0.41 (0.15 – 1.13) 0.62 (0.20 – 1.87) 
     Age ≥ 30 at first birth 7,855 1.01 (0.46 – 2.21) 1.05 (0.48 – 2.34) 
High socio-economic status 4 5,268 0.46 (0.16 – 1.30) 0.36 (0.12 – 1.03) 
Diagnoses at baseline    
     PID 3,885 0.94 (0.36 – 2.45) 0.96 (0.37 – 2.51) 
     Endometriosis 2,978 0.26 (0.04 – 1.92) 0.31 (0.04 – 2.29) 
Procedures    
     Sterilization 3,740 1.55 (0.66 – 3.63) 1.48 (0.63 – 3.48) 
     Hysterectomy without USO 5 2,186 1.01 (0.24 – 4.34) 1.02 (0.24 – 4.37) 
 376 
1 The crude HR is estimated from a model that includes only the variable listed. In each case, it 377 
compares the rate of borderline ovarian tumors in women in the exposed group with all other 378 
women in the cohort. 379 
2 Each adjusted HR is estimated from a separate model that includes the variable listed, plus IVF, 380 
socio-economic status, age and calendar year at the first infertility admission. 381 
3 Women known to have given birth were compared with women who had no recorded births. 382 
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4 Socio-economic status was measured using the Index of Education and Occupation. Women in the 383 
upper quartile were compared with women in the lower three quartiles combined. 384 
5 A further 690 women had a hysterectomy and a USO, either in the same or separate admissions. 385 
None of these were diagnosed with borderline ovarian tumors. A total of 497 women had a USO 386 
without hysterectomy in the same or any other admission. None of these were diagnosed with 387 
borderline ovarian tumors more than 12 months after USO. 388 
